natgillin/translations-raw huggingface dataset:
Interaktionen mellem rilpivirin og lægemidlet blev vurderet i et klinisk studie.
The interaction between rilpivirine and the medicinal product was evaluated in a clinical study.
Interaktionen ved administration sammen med de lægemidler, der er nævnt i tabel 2, er af samme størrelsesorden (en forskel på ≤ 25 % i mindste kvadraters gennemsnit) for Viekirax-regimer med og uden dasabuvir, medmindre andet er angivet.
The magnitude of interaction when administered with medicinal products listed in Table 2 are similar (≤25% difference in the Least Square Means ratio) for Viekirax with or without dasabuvir, unless otherwise noted.
Interaktioner
Interaction:
Interaktioner hos patienter med nedsat CYP2D6-metabolisme
Interactions in CYP2D6 poor metabolisers
Interaktioner med anden medicin mod hiv: etravirin tilhører typen af hiv-medicin, der kaldes non-nukleosid revers-transkriptase-hæmmere (NNRTI).
Interactions with other HIV medicines: etravirine belongs to a class of HIV medicines called non-nucleoside reverse transcriptase inhibitors (NNRTIs).
Interaktioner med andre lægemidler
Drug-drug interactions
Interaktioner med andre lægemidler og andre former for interaktion
Interaction with other medicinal products and other forms of interaction
Interaktioner med andre lægemidler og andre former for interaktion
Interaction with other medicinal products and other forms of interaction:
Interaktioner med andre lægemidler og andre former for interaktion:
Interaction with other medicinal products and other forms of interaction
Interaktioner med andre lægemidler og andre former for interaktion:
Interactions with other medical products and other forms of interaction:
Interaktioner med andre lægemidler og andre interaktioner:
Interaction with other medicinal products and other forms of interaction:
Interaktioner med andre lægemidler, der påvirker hæmostasen
Interaction with other medicinal products affecting haemostasis
Interaktioner med andre lægemidler:
Interactions with other medicinal products
Interaktioner med andre præparattyper er ikke undersøgt specifikt.
Interactions with other drug types have not been specifically investigated.
Interaktioner med CYP
CYP450 interactions
Interaktioner med doxorubicin er også rapporteret for streptozocin, phenobarbital, phenytoin og warfarin.
Interactions with doxorubicin have also been reported for streptozocin, phenobarbital, phenytoin and warfarin.
Interaktioner med kaliumbesparende diuretika såsom spironolakton, triamteren eller amilorid kan ikke udelukkes.
Interactions with potassium-preserving diuretics like spironolactone, triamterene or amiloride cannot be ruled out.
Interaktioner med mad
Food interaction
Interaktioner med P-glykoprotein (P-gp)
P-glycoprotein (P-gp) interactions
Interaktioner med P-glykoprotein (P-gp)-hæmmere
Interactions with P-glycoprotein (P-gp) inhibitors
Interaktioner med P-gp
P-gp interactions
Interaktioner med systemiske lægemidler ville blive begrænset af den minimale perkutane absorption af imiquimod creme.
Interactions with systemic drugs would be limited by the minimal percutaneous absorption of imiquimod cream.
Interaktioner med transportsystemer for lægemiddeloptagelse
Interactions with drug uptake transport systems
Interaktioner medieret af virkninger på transportører
Interactions mediated by effects on transporters
Interaktioner mellem cobicistat og mulige samtidigt administrerede lægemidler ses i tabel 2 nedenfor (stigning er angivet som "↑", fald som "↓", ingen ændring som "↔").
Interactions of cobicistat and potential co-administered medicinal products are listed in Table 2 below (increase is indicated as “↑”, decrease as “↓”, no change as “↔”).
Interaktioner mellem darunavir/ritonavir og antiretrovirale og non-antiretrovirale lægemidler er opført i tabellen nedenfor (ikke fastsat (not determined) som ”ND”).
Interactions between darunavir/ritonavir and antiretroviral and non-antiretroviral medicinal products are listed in the table below (not determined as “ND”).
Interaktioner mellem dolutegravir og samtidigt administrerede lægemidler er anført i tabel 1 (stigning er angivet som "↑", fald som "↓", ingen ændring som "↔", arealet under koncentrations-tids-kurven som "AUC" den observerede maksimumskoncentration som "Cmax" og koncentrationen ved slutningen af doseringsinterval som ” Cτ”).
Interactions between dolutegravir and co-administered medicinal products are listed in Table 1 (increase is indicated as “↑”, decrease as “↓”, no change as “↔”, area under the concentration versus time curve as “AUC”, maximum observed concentration as “Cmax”, concentration at end of dosing interval as “Cτ”).
Interaktioner mellem Emtricitabine/Tenofovir disoproxil Zentiva eller dets individuelle komponent(er) og andre lægemidler ses i Tabel 2 nedenfor (stigning er angivet som „↑“, fald som
Interactions between Emtricitabine/Tenofovir disoproxil Zentiva or its individual component(s) and other medicinal products are listed in Table 2 below (increase is indicated as “↑”, decrease as “↓”
Interaktioner mellem Epclusa og andre lægemidler
Interactions between Epclusa and other medicinal products
Interaktioner mellem Ilaris og andre lægemidler er ikke undersøgt i formelle studier.
Interactions between Ilaris and other medicinal products have not been investigated in formal studies.
Interaktioner mellem indinavir/ritonavir og andre lægemidler fremgår af tabellerne nedenfor (stigning er vist som "↑", fald som "↓", ingen ændring (≤ +/-20%) som "↔", enkeltdosis som "SD", én gang daglilgt som "QD", to gange dagligt som "BID", tre gange dagligt som "TID", og fire gange dagligt som "QID").
Interactions between indinavir/ritonavir and other medicinal products are listed in the tables below (increase is indicated as “↑”, decrease as “↓”, no change (≤ +/- 20 %) as “↔”, single dose as “SD”, once daily as “QD”, twice daily as “BID”, three times daily as “TID”, and four times daily as "QID").
Interaktioner mellem komponenterne i DUTREBIS og samtidigt administrerede lægemidler er oplistet i tabel 1 nedenfor.
Interactions between the components of DUTREBIS and co-administered medicinal products are listed in Table 1 below.
Interaktioner mellem lægemiddel og laboratorietest
Drug/laboratory test interactions
Interaktioner mellem Nonafact og andre lægemidler er ikke kendt.
No interactions of Nonafact with other medicinal products are known.
Interaktioner mellem rilpivirin og samtidigt indgivne lægemidler er angivet i tabel 1 (forhøjelse angives med "↑", reduktion angives med "↓", ingen ændring angives med "↔", ikke relevant angives med "IR", konfidensinterval angives med "CI", en gang dagligt angives med ”x 1”, to gange dagligt angives med ”x 2”).
Interactions between rilpivirine and co-administered medicinal products are listed in table 1 (increase is indicated as “↑”, decrease as “↓”, no change as “↔”, not applicable as “NA”, confidence interval as “CI”).
Interaktioner mellem tenofovirdisoproxilfumarat og andre lægemidler ses i tabel 1 nedenfor (stigning er angivet som „↑“, fald som „↓“, ingen ændring som „↔“, to gange dagligt som „b.i.d.“, en gang dagligt som „q.d.“).
Interactions between tenofovir disoproxil fumarate and other medicinal products are listed in Table 1 below (increase is indicated as “↑”, decrease as “↓”, no change as “↔”, twice daily as “b.i.d.”, and once daily as “q.d.”).
Interaktioner mellem tenofovirdisoproxilfumarat og andre lægemidler ses i tabel 2 nedenfor (stigning er angivet som „↑“, fald som „↓“, ingen ændring som „↔“, to gange dagligt som „b.i.d.“, en gang dagligt som „q.d.“).
Interactions between tenofovir disoproxil fumarate and other medicinal products are listed in Table 2 below (increase is indicated as “↑”, decrease as “↓”, no change as “↔”, twice daily as “b.i.d.”, and once daily as “q.d.”).
INTERAKTIONER OG DOSISANBEFALINGER MED ANDRE LÆGEMIDLER
INTERACTIONS AND DOSE RECOMMENDATIONS WITH OTHER MEDICINAL PRODUCTS
Interaktioner og dosisrekommandationer sammen med andre lægemidler – IKKE- BOOSTET INDINAVIR
Interactions and dose recommendations with other medical products – UNBOOSTED INDINAVIR
Interaktioner og dosisrekommandationer sammen med andre lægemidler – INDINAVIR BOOSTET MED INDINAVIR.
Interactions and dose recommendations with other medical products – INDINAVIR BOOSTED WITH RITONAVIR.
Interaktioner, der er relevante for monoterapi
Interactions relevant to monotherapies
Interaktioner, der kræver forsigtighed
Interactions requiring caution
Interaktioner, der potentielt kan påvirke olanzapin
Potential interactions affecting olanzapine:
Interaktioner, derpotentielt kan påvirke olanzapin
Potential interactions affecting olanzapine
Interaktions forsøg har vist, at pioglitazon ikke har relevant effekt på hverken farmakokinetikken eller farmakodynamikken af digoxin, warfarin, phenprocoumon og metformin.
Interaction studies have shown that pioglitazone has no relevant effect on either the pharmacokinetics or pharmacodynamics of digoxin, warfarin, phenprocoumon and metformin.
Interaktions studier er kun udført hos voksne.
Interaction studies have only been performed in adults.
Interaktionsdata er ikke tilgængelige vedr. administration af indinavir/ritonavir og amprenavir.
There are no interaction data available on the coadministration of indinavir/ritonavir and amprenavir.
Interaktionsforsøg har vist, at pioglitazon ikke har relevant effekt på hverken farmakokinetikken eller farmakodynamikken af digoxin, warfarin, phenprocoumon og metformin.
Interaction studies have shown that pioglitazone has no relevant effect on either the pharmacokinetics or pharmacodynamics of digoxin, warfarin, phenprocoumon and metformin.
Interaktionsforsøg har vist, at pioglitazon ikke har relevant effekt på hverken farmakokinetikken eller farmakodynamikken egenskaber af digoxin, warfarin, phenprocoumon og metformin.
Interaction studies have shown that pioglitazone has no relevant effect on either the pharmacokinetics or pharmacodynamics of digoxin, warfarin, phenprocoumon and metformin.
Interaktionsforsøg har vist, at pioglitazon ikke har relevant effekt på hverken farmakokinetikken eller farmakodynamikken for digoxin, warfarin, phenprocoumon og metformin.
Interaction studies have shown that pioglitazone has no relevant effect on either the pharmacokinetics or pharmacodynamics of digoxin, warfarin, phenprocoumon or metformin.
Interaktionsforsøg har vist, at pioglitazon ikke har relevant effekt på hverken farmakokinetikken eller farmakodynamikken hos digoxin, warfarin, phenprocoumon og metformin.
Interaction studies have shown that pioglitazone has no relevant effect on either the pharmacokinetics or pharmacodynamics of digoxin, warfarin, phenprocoumon and metformin.
Interaktionsforsøg med cimetidin (non- specifik cytochrom P450 hæmmer) og rifampicin (non-specifik cytochrom P450 inducer) tyder på, at CYP enzymer in vivo kun er ansvarlig for en lille del af metaboliseringen af leflunomid.
Interaction studies with cimetidine (non-specific cytochrome P450 inhibitor) and rifampicin (non-specific cytochrome P450 inducer), indicate that in vivo CYP enzymes are involved in the metabolism of leflunomide only to a small extent.
Interaktionsforsøg viste, at lacosamid ikke havde nogen effekt på digoxins farmakokinetik.
Interaction trials showed that lacosamide had no effect on the pharmacokinetics of digoxin.
Interaktionsmekanismen
The mechanism of
Interaktionsmekanismen er
The mechanism of interaction is
Interaktionsmekanismen er
The mechanism of interaction is a
Interaktionsmekanismen er atazanavir- og/eller ritonavir- hæmning af CYP3A4.
The mechanism of interaction is CYP3A4 inhibition by atazanavir and/or ritonavir.
Interaktionsmekanismen er atazanavir- og/eller ritonavir- hæmning af CYP3A4.
The mechanism of interaction is CYP3A4 inhibition by atazanavir/ritonavir.
Interaktionsmekanismen er atazanavirs og cobicistats CYP3A4-hæmning.
The mechanism of interaction is CYP3A4 inhibition by atazanavir and cobicistat.
Interaktionsmekanismen er cobicistats CYP3A4-hæmning.
The mechanism of interaction is inhibition of CYP3A4 by
Interaktionsmekanismen er CYP3A4- hæmning.
The mechanism of interaction is CYP3A4 inhibition.
Interaktionsmekanismen er ikke fuldstændig klarlagt.
The mechanism of the interaction has not been completely clarified.
Interaktionsmekanismen er nedsat opløselighed af atazanavir pga. intragastrisk pH-stigning med H2- blokkere.
The mechanism of interaction is decreased solubility of atazanavir as intra-gastric pH increases with H2 blockers.
Interaktionsmekanismen er REYATAZ- og/eller ritonavir- hæmning af CYP3A4.
The mechanism of interaction is CYP3A4 inhibition by atazanavir/ritonavir.
Interaktionsmekanismen er REYATAZ- og/eller ritonavir- hæmning af CYP3A4.
The mechanism of interaction is CYP3A4 inhibition by REYATAZ and/or ritonavir.
Interaktionsmekanismen for
The mechanism of the
Interaktionsmekanismen for amiodaron eller systemisk lidocain/atazanavir er CYP3A- hæmning.
The mechanism of amiodarone or systemic lidocaine/atazanavir interaction is CYP3A inhibition.
Interaktionsmekanismen mellem
The mechanism of interaction
Interaktionsmekanismen mellem
The mechanism of interaction between
Interaktionsprofilen for hiv-proteasehæmmere ved samtidig indgift af lave doser af ritonavir afhænger af den konkrete samtidigt indgivne proteasehæmmer.
The interaction profiles of HIV-protease inhibitors, co-administered with low dose ritonavir, are dependent on the specific co-administered protease inhibitor.
interaktionsstudie med raske
tudy in healthy volunteers
interaktionsstudier
Cyclosporin
interaktionsstudier
No interaction study
interaktionsstudier
No interaction study performed
interaktionsstudier
performed
Interaktionsstudier er kun udført hos voksne.
Interaction studies have been performed only in adults.
Interaktionsstudier er kun udført hos voksne.
Interaction studies have only been performed in adults
Interaktionsstudier er kun udført hos voksne.
Interaction studies with these agents have only been performed in adults.
Interaktionsstudier er udført med labetalol og betamethasone hos raske, frivillige kvinder.
Interaction studies have been performed with labetalol and betamethasone in healthy, female volunteers.
Interaktionsstudier erkun udført hos voksne.
Interaction studies have only been performed in adults.
Interaktionsstudier med exenatid er kun udført hos voksne.
Interaction studies with exenatide have only been performed in adults.
Interaktionsstudier med itraconazol og ketoconazol, to CYP3A4-inhibitorer, viste, at maksimum- plasmakoncentrationerne af telithromycin steg henholdsvis 1,22 og 1,51 gange og AUC henholdsvis 1,54 og 2,0 gange.
Interaction studies with itraconazole and ketoconazole, two CYP3A4 inhibitors, showed that maximum plasma concentrations of telithromycin were increased respectively by 1.22 and 1.51 fold and AUC by respectively 1.54 fold and 2.0 fold.
Interaktionsstudier udført på raske forsøgspersoner hovedsageligt med enkeltdosisdesign tyder på, at farmakokinetikken af dapagliflozin ikke ændres af metformin, pioglitazon, sitagliptin, glimepirid, hydrochlorthiazid, bumetanid, valsartan eller simvastatin.
Interaction studies conducted in healthy subjects, using mainly a single dose design, suggest that the pharmacokinetics of dapagliflozin are not altered by metformin, pioglitazone, sitagliptin, glimepiride, voglibose, hydrochlorothiazide, bumetanide, valsartan, or simvastatin.
Interaktionsstudier udført på raske forsøgspersoner hovedsageligt med enkeltdosisdesign tyder på, at farmakokinetikken af dapagliflozin ikke ændres af pioglitazon, sitagliptin, glimepirid, voglibose, hydrochlorthiazid, bumetanid, valsartan eller simvastatin.
Interaction studies conducted in healthy subjects, using mainly a single-dose design, suggest that the pharmacokinetics of dapagliflozin are not altered by pioglitazone, sitagliptin, glimepiride, voglibose, hydrochlorothiazide, bumetanide, valsartan, or simvastatin.
interaktionsstudier.
performed
Interaktionsstudierer kun udført hos voksne.
Interaction studies have only been performed in adults.
Interaktionsundersøgelser har ikke påvist nogen klinisk relevant forsinkelse af absorptionen og derfor er det ikke nødvendigt at justere dosis.
Interaction studies did not show any clinically relevant delay of absorption and therefore no dose adjustment is required.
Interferens kan forekomme i nærheden af udstyr, der er mærket med følgende symbol:
Interference may occur in the vicinity of equipment marked with the following symbol:
Interferens med bestemmelse af komplet respons
Interference with determination of Complete Response
Interferens med indirekte antiglobulintest (Indirekte Coombs test)
Interference with Indirect Antiglobulin Test (Indirect Coombs Test)
Interferens med mitokondriel elektrontransport.
Interference with mitochondrial electron transport
Interferens med parasittens transportproteiner.
Interference with parasite transport proteins
Interferens med serumproteinelektroforese- og immunfikseringstest
Interference with Serum Protein Electrophoresis and Immunofixation Tests
Interfero n alfa-2a 3 MIE
Interferon alfa-2a 3 MIU
Interferon alfa, interferon beta og interferon gamma har over- lappende og alligevel adskilte biologiske virkninger.
Interferon alpha, interferon beta, and interferon gamma have overlapping yet distinct biologic activities.
Interferon alfa-2a 3MIE & ribavirin 800 mg vs.
Interferon alfa-2a 3 MIU & ribavirin 800 mg vs.
Interferon alfa-2a i Pegasys fremstilles ved en metode, der kaldes "rekombinant DNA-teknologi": Det fremstilles af bakterier, der har fået indsat et gen (DNA), som gør dem i stand til at producere interferon alfa-2a.
The interferon alfa-2a in Pegasys is produced by a method known as ‘recombinant DNA technology’: it is made by bacteria into which a gene (DNA) has been introduced, which makes them able to produce interferon alfa-2a.
Interferon alfa-2b (3 MIE TIW)
Interferon alfa-2b (3 MIU TIW)
Interferon alfa-2b (3 MIE TIW) +
Interferon alfa-2b (3 MIU TIW) +
Interferon alfa-2b (3 MIE tre gange om ugen) + ribavirin (1.000/1.200 mg/dag) (n = 505).
Interferon alfa-2b (3 MIU three times a week) + ribavirin (1,000/1,200 mg/day) (n = 505).
Interferon alfa-2b (pegyleret og ikke-pegyleret)-behandling kan initieres, hvis TSH-niveauet kan fastholdes inden for normalområdet ved medicinsk behandling.
Interferon alfa-2b (pegylated and non-pegylated) therapy may be initiated if TSH levels can be maintained in the normal range by medication.
Interferon alfa-2b er vist at være abortfremkaldende i primater.
Interferon alfa-2b has been shown to be an abortifacient in primates.
Interferon alfa-2b har vist sig at være abortfremkaldende hos primater.
Interferon alfa-2b has been shown to be abortifacient in primates.
Interferon alfa-2b i IntronA produceres ved en metode, der kaldes "rekombinant DNA- teknologi": Det produceres af en bakterie, der har modtaget et gen (DNA), som sætter bakterien i stand til at producere interferon alfa-2b.
The interferon alfa-2b in IntronA is produced by a method known as ‘recombinant DNA technology’: it is made by a bacterium that has received a gene (DNA), which makes it able to produce interferon alfa-2b.
Interferon alfa-2b i PegIntron fremstilles ved hjælp af en metode, der kaldes "rekombinant DNA-teknologi": Det fremstilles af en bakterie, der har fået indsat et gen (DNA), som sætter den i stand til at producere interferon alfa-2b.
The interferon alfa-2b in PegIntron is produced by a method known as ‘recombinant DNA technology’: it is made by a bacterium that has received a gene (DNA), which makes it able to produce interferon alfa-2b.
Interferon alfa-2b i ViraferonPeg fremstilles ved hjælp af en metode, der kaldes "rekombinant DNA-teknologi": Det fremstilles af en bakterie, der har fået indsat et gen (DNA), som sætter den i stand til at producere interferon alfa-2b.
The interferon alfa-2b in ViraferonPeg is produced by a method known as ‘recombinant DNA technology’: it is made by a bacterium that has received a gene (DNA), which makes it able to produce interferon alfa-2b.
Interferon alfa/ribavirin
interferon alpha/ribavirin
Interferon beta 1-a er en form af et protein, der dannes naturligt i kroppen.
Interferon beta 1-a is a form of a protein that is naturally produced by the body.
Interferon beta-1a metaboliseres og udskilles hovedsageligt gennem lever og nyrer.
Interferon beta-1a is mainly metabolised and excreted by the liver and the kidneys.
Interferon beta-1a produceres ved en metode, der er kendt som "rekombinant DNA-teknologi": Interferon beta-1a produceres af en celle, der har fået indsat et gen (dna), som gør den i stand til at producere det.
Interferon beta-1a is produced by a method known as ‘recombinant DNA technology’: the interferon beta-1a is made by a cell that has received a gene (DNA), which makes it able to produce it.
Interferon beta-1a produceres ved en metode, der kaldes "rekombinant DNA-teknologi": Det fremstilles af celler, som har fået indsat et gen (DNA), der sætter dem i stand til at producere interferon beta-1a.
Interferon beta-1a is produced by a method known as ‘recombinant DNA technology’: it is made by cells into which a gene (DNA) has been introduced, which makes them able to produce interferon beta-1a.
Interferon beta-1a s.c. anvendelse
Interferon beta-1a SC use
Interferon beta-1b både nedsætter bindingsaffiniteten og øger samtidig internaliseringen og nedbrydningen af inteferon-gamma receptorerne.
Interferon beta-1b both decreases the binding affinity and enhances the internalisation and degradation of the interferon-gamma receptor.
Interferon beta-1b fremstilles ved "rekombinant DNA-teknologi".
Interferon beta-1b is produced by a method known as ‘recombinant DNA technology’.
Interferon beta-1b nedsætter bindingsaffiniteten og øger internaliseringen og nedbrydningen af inteferon-gamma receptorerne.
Interferon beta-1b both decreases the binding affinity and enhances the internalisation and degradation of the interferon-gamma receptor.
Interferon beta-1b produceres af en bakterie, der har fået indsat et gen (dna), som gør den i stand til at producere stoffet.
The interferon beta-1b is made by a bacterium that has received a gene (DNA), which makes it able to produce it.
Interferon beta-1b produceres af en celle, der har fået indsat et gen (dna), som gør den i stand til at producere stoffet.
The interferon beta-1b is made by a bacterium that has received a gene (DNA), which makes it able to produce it.
interferon eller ribavirin
or ribavirin can be
interferon mod virusinfektioner
interferon, to treat viral infections
interferon mod virusinfektioner.
interferon, to treat viral infections
Interferon monoterapi, inklusive ViraferonPeg, er hovedsageligt indiceret i tilfælde af intolerance eller kontraindikation over for ribavirin.
Interferon monotherapy, including ViraferonPeg, is indicated mainly in case of intolerance or contraindication to ribavirin.
interferon, til behandling af virusinfektioner
interferon, to treat viral infections
Interferon- alpha
Interferon alpha
Interferon-klassifikation
Interferon classification
interferoner (immunstimulerende midler), som tages med eller uden ribavirin – anvendes til behandling af hepatitis.
interferons taken with or without ribavirin – used to treat hepatitis.
Interferoner er cytokiner, der formidler antivirale, antiproliferative og immunmodulerende aktiviteter.
Interferons are cytokines that mediate antiviral, antiproliferative and immunomodulatory activities.
Interferoner er naturlige stoffer, der produceres af kroppen som forsvar mod virusinfektioner.
Interferons are natural substances produced by the body that help it fight infections caused by viruses.
Interferoner er proteiner, der dannes af kroppen og som hjælper immunsystemet med at bekæmpe f.eks. luftvejsinfektioner.
Interferons are proteins produced by the body that help it fight against attacks on the immune system such as viral infections.
Interferoner og Viramune kan co- administreres uden dosisjustering.
Interferons and Viramune may be coadministered without dose adjustments.
Interferoner produceres af kroppens immunsystem for at bekæmpe infektioner og alvorlige sygdomme.
Interferons are made by your body’s immune system to help fight infections and severe diseases.